Ritter Pharmaceuticals, Inc., a developer of novel therapeutics to treat gastrointestinal diseases, has signed an agreement with Medpace to conduct the first of two pivotal Phase III clinical trials for RP-G28 in patients with lactose intolerance (LI). With support from Medpace, Ritter will conduct a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in the U.S., in approximately 525 patients to evaluate the efficacy, safety, durability, and tolerability of RP-G28...